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Association between glaucoma 
surgery and all‑cause 
and cause‑specific mortality 
among elderly patients 
with glaucoma: a nationwide 
population‑based cohort study
Sang Yeop Lee1,2,6, Hun Lee3,6, Ji Sung Lee4,5, Sol Ah Han3, Yoon Jeon Kim3, Jae Yong Kim3 & 
Hungwon Tchah3*
This population‑based, retrospective cohort study aimed to evaluate the association between 
glaucoma surgery and all‑cause and cause‑specific mortality among Korean elderly patients with 
glaucoma. A total of 16210 elderly patients (aged ≥ 60 years) diagnosed with glaucoma between 2003 
and 2012 were included, and their insurance data were analyzed. The participants were categorized 
into a glaucoma surgery cohort (n = 487), which included individuals who had diagnostic codes for 
open angle glaucoma (OAG) or angle closure glaucoma (ACG) and codes for glaucoma surgery, 
and a glaucoma diagnosis cohort (n = 15,723), which included patients who had codes for OAG and 
ACG but not for glaucoma surgery. Sociodemographic factors, Charlson Comorbidity Index score, 
and ocular comorbidities were included as covariates. Cox regression models were used to assess 
the association between glaucoma surgery and mortality. The incidence of all‑cause mortality was 
34.76/1,000 person‑years and 27.88/1,000 person‑years in the glaucoma surgery and diagnosis 
groups, respectively. The adjusted hazard ratio (HR) for all‑cause mortality associated with glaucoma 
surgery was 1.31 (95% confidence interval [CI], 1.05–1.62, P = 0.014). The adjusted HR for mortality 
due to a neurologic cause was significant (HR = 2.66, 95% CI 1.18–6.00, P = 0.018). The adjusted HRs 
for mortality due to cancer (HR = 2.03, 95% CI 1.07–3.83, P = 0.029) and accident or trauma (HR = 4.00, 
95% CI 1.55–10.34, P = 0.004) associated with glaucoma surgery for ACG were significant as well. 
Glaucoma surgery was associated with an increase of mortality in elderly patients with glaucoma. 
In particular, the risk of mortality associated with glaucoma surgery due to neurologic causes was 
significant.
Glaucoma is a leading cause of irreversible blindness and is expected to affect more than 100 million people 
worldwide by  20401,2. Reduced vision due to glaucoma progression negatively affects a patient’s quality of  life3. 
In a recent study of mortality and causes of death among the individuals with blindness in  Korea4, the mortality 
risk recorded in the blindness group was 1.54 times higher than that of the control group. As glaucoma and visual 
impairment including blindness are closely related, an association between glaucoma and mortality is expected.
Using topical medications for the reduction of intraocular pressure (IOP) is considered the first line treat-
ment for glaucoma. Surgical treatment is considered when the medical treatment does not sufficiently reduce 
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IOP to decrease the rate of glaucomatous damage. Medical treatment is often combined with surgical treatment. 
However, since surgical treatment is used to induce maximum IOP reduction, the glaucoma status of patients 
who underwent glaucoma surgery is likely to differ from that of patients who only received medical treatment. 
Although previous studies have investigated the association between glaucoma and  mortality5–16, none have 
studied the association between glaucoma surgery and mortality.
Therefore, we conducted this study to verify the association between glaucoma surgery and total and cause-
specific mortality using the Korean National Health Insurance Service-Senior cohort (KNHIS-Senior), which is 
a nationwide cohort database that represents the entire elderly Korean population.
Results
Baseline characteristics. Table 1 shows the characteristics of patients with and without a history of glau-
coma surgery. The study cohort included 16,210 patients with glaucoma (mean [SD] age, 72.6 [5.6] years). 
Among them, 487 patients underwent glaucoma surgery, and 15,723 patients did not undergo glaucoma surgery. 
Patients aged > 70 years tended not to opt for glaucoma surgery (absolute standardized difference, ASD = 0.228). 
Additionally, the individuals in the glaucoma surgery group were significantly younger than those in the glau-
coma diagnosis group (ASD = 0.237). There were no significant differences between both groups regarding other 
variables except the ratio of patients who had diabetes mellitus (DM) with ophthalmic manifestations. A sig-
nificantly greater ratio of patients having DM with ophthalmic manifestations were identified in the glaucoma 
surgery group than in the glaucoma diagnosis group (ASD = 0.135).
Incidence of mortality. Table 2 indicates the mortality rates of elderly Korean patients with or without a 
history of glaucoma surgery. The incidence of mortality by all causes was 34.76 deaths per 1000 person-years in 
the glaucoma surgery group and 27.88 deaths per 1000 person-years in the glaucoma diagnosis group. The inci-
dence of mortality due to neurologic causes showed remarkable differences between groups. It was 2.51 deaths 
per 1000 person-years in the glaucoma surgery group and 0.93 deaths per 1000 person-years in the glaucoma 
diagnosis group.
Table 3 shows the hazard ratio (HR) for all-cause and cause-specific mortality in elderly patients with or 
without a history of glaucoma surgery. One unadjusted Cox model and three adjusted Cox models were identi-
fied in the analysis of the adjusted variables. Patients who had a history of glaucoma surgery were more prone 
to all-cause mortality than were those without a history of glaucoma surgery. The HRs for all-cause mortality 
in all the adjusted Cox models were significant (HR = 1.28, 95% confidence interval, CI 1.03–1.59, P = 0.023 
in model 1; HR = 1.29, 95% CI 1.04–1.60, P = 0.02 in model 2; and HR = 1.31, 95% CI 1.05–1.62, P = 0.014 in 
model 3). Analysis of cause-specific HRs showed that only the HRs for mortality due to neurologic causes were 
significant in all Cox models. In the unadjusted Cox model, the HR was 2.3, with a 95% CI ranging from 1.02 to 
5.22 (P = 0.045). Additionally, the HRs for mortality related to neurologic causes were 2.59 (95% CI 1.15–5.84, 
P = 0.022), 2.71 (95% CI 1.20–6.12, P = 0.017), and 2.66 (95% CI 1.18–6.00, P = 0.018) in Cox model 1, model 2, 
and model 3, respectively.
The HRs for the incidence of mortality related with glaucoma surgery after the adjustment of covariates are 
presented in Table 4. All variables except age 75 to 79 years, Charlson comorbidity index (CCI) score of 3, and 
an ex-smoker status showed HRs greater than 1. However, analysis of the interaction between these variables 
and the effect of glaucoma surgery on mortality showed no significant results.
We investigated the HRs for cause-specific mortality according to the history of glaucoma surgery for open 
angle glaucoma (OAG) and angle closure glaucoma (ACG) (Table 5). The baseline characteristics of patients who 
had OAG and ACG are presented in Supplementary Tables S1 and S2. For OAG, there were no significant HRs 
for cause-specific mortality related with glaucoma surgery in all unadjusted and adjusted analyses. However, for 
ACG, the HRs for total mortality and mortality caused by accident or trauma were significant in the unadjusted 
and adjusted analyses. After adjusting for all variables (model 3), the HR of all-cause mortality and mortality 
caused by accident or trauma was 1.82 (95% CI 1.27–2.62, P = 0.001) and 4.00 (95% CI 1.55–10.34, P = 0.004), 
respectively. Additionally, increase of cancer mortality was significantly associated with glaucoma surgery for 
ACG. Regarding the results of the adjusted Cox models, the HR of cancer-related mortality was 1.99 (95% CI 
1.07–3.71, P = 0.03), 2.03 (95% CI 1.08–3.84, P = 0.028), and 2.03 (95% CI 1.07–3.83, P = 0.029) in models 1, 2, 
and 3, respectively.
Discussion
In the present study of patients with OAG and ACG, the glaucoma surgery group had a higher mortality rate 
than that of the glaucoma diagnosis group, regardless of the cause of mortality. Additionally, after adjusting for 
variables including demographic factors and systemic and ocular comorbidities, the hazard of all-cause mortality 
in elderly patients who underwent glaucoma surgery increased by about 30% compared with that of patients who 
did not undergo glaucoma surgery. Moreover, the risk of mortality due to neurologic causes was significantly 
higher in elderly patients who underwent glaucoma surgery than in those who did not.
The association between glaucoma and neurologic disease has been investigated in several previous studies by 
evaluating pathogenic mechanisms like neurotoxicity caused by amyloid-beta, Tau protein, autophagy downregu-
lation, dopamine depletion, and alteration of the hemodynamics of a cerebral artery with white matter  lesions17. 
Several experts have suggested a correlation between glaucoma and  stroke18–21. Alzheimer’s  disease22–24 and 
Parkinson’s  disease25–27 are representative neurologic disorders that are reportedly associated with glaucoma. In 
studies using brain magnetic resonance imaging, structural and functional alterations were observed in patients 
with  glaucoma25–27. These results support the hypothesis that glaucoma should be considered a central nervous 
system disorder. In the present study, the incidence of mortality due to neurologic causes was noticeably different 
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between the glaucoma surgery group (2.51 per 1000 person-years) and the glaucoma diagnosis group (0.93 per 
1000 person-years). Additionally, glaucoma surgery was significantly associated with a > 2.5 time increase of HR 
for mortality due to neurologic causes, even after all variables were adjusted. These results show the importance 
of assessing patients, especially those with OAG or ACG who have undergone glaucoma surgery, for neurologi-
cal disorders.
The analysis of HRs for mortality related with glaucoma surgery, which were stratified according to covari-
ates, showed that almost all HRs were > 1 (Table 3). In particular, the HRs adjusted for age below 70 years, male, 
residing in a metropolitan area, income below the 20th percentile, a CCI score of 2 and ≥ 5, no age-related 
macular degeneration, no severe cataract, non-smoking, no alcohol consumption, regular exercise, and body 
mass index (BMI) under 23 kg/m2 were significant. These are conditions thought to decrease the morbidity of 
Table 1.  Baseline characteristics of patients according to history of glaucoma surgery. BMI body mass index, 
CCI Charlson Comorbidity Index, DM diabetes mellitus, ASD absolute standardized difference. Data are 
expressed as mean ± standard deviation (SD) or n (%). a ASD of > 0.1 is considered a meaningful imbalance.
Variable Total (n = 16,210) Surgery group (n = 487) Non-surgery group (n = 15,723) ASDa
Age (years) 0.228
 < 70 4862 (30.0) 192 (39.4) 4670 (29.7)
70–74 5912 (36.5) 165 (33.9) 5747 (36.6)
75–79 3509 (21.6) 89 (18.3) 3420 (21.8)
80–84 1454 (9.0) 34 (7.0) 1420 (9.0)
 ≥ 85 473 (2.9) 7 (1.4) 466 (3.0)
Mean ± SD 72.6 ± 5.6 71.4 ± 5.4 72.7 ± 5.6 0.237
Sex 0.022
Male 7051 (43.5) 217 (44.6) 11,646 (40.0)
Female 9159 (56.5) 270 (55.4) 17,498 (60.0)
Residence 0.036
Metropolitan 7033 (43.4) 203 (41.7) 6830 (43.4)
Provincial 9177 (56.6) 284 (58.3) 8893 (56.6)
Income 0.050
Below 20 percentiles 2954 (18.2) 98 (20.1) 2856 (18.2)
Above 20 percentiles 13,256 (81.8) 389 (79.9) 12,867 (81.8)
CCI 0.077
0 1798 (11.1) 57 (11.7) 1741 (11.1)
1 2742 (16.9) 82 (16.8) 2660 (16.9)
2 2885 (17.8) 94 (19.3) 2791 (17.8)
3 2519 (15.5) 77 (15.8) 2442 (15.5)
4 2052 (12.7) 65 (13.3) 1987 (12.6)
 ≥ 5 4214 (26.0) 112 (23.0) 4102 (26.1)
BMI (kg/m2) 23.9 ± 3.2 23.9 ± 3.2 23.9 ± 3.2 0.019
Smoking status 0.060
Non-smoker 12,847 (79.3) 393 (80.7) 12,454 (79.2)
Ex-smoker 1601 (9.9) 40 (8.2) 1561 (9.9)
Current smoker 1762 (10.9) 54 (11.1) 1708 (10.9)
Alcohol consumption 0.041
No 12,581 (77.6) 386 (79.3) 12,195 (77.6)
Yes 3629 (22.4) 101 (20.7) 3528 (22.4)
Regular exercise 0.028
No 13,381 (82.5) 407 (83.6) 12,974 (82.5)
Yes 2829 (17.5) 80 (16.4) 2749 (17.5)
Age-related macular degeneration 0.019
No 15,603 (96.3) 467 (95.9) 15,136 (96.3)
Yes 607 (3.7) 20 (4.1) 587 (3.7)
DM with ophthalmic manifestations 0.135
No 15,609 (96.3) 455 (93.4) 15,154 (96.4)
Yes 601 (3.7) 32 (6.6) 569 (3.6)
Severe cataract 0.040
No 12,968 (80.0) 397 (81.5) 12,571 (80.0)
Yes 3242 (20.0) 90 (18.5) 3152 (20.0)
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ocular or systemic diseases. Since there were no significant p-values for interaction even though there were sig-
nificant adjusted HRs, further studies are needed to determine the role of these conditions in increasing the risk 
of mortality in patients who have undergone glaucoma surgery. However, the results of the present study show 
that the hazard of mortality related with glaucoma surgery can increase even if conditions that increase the pos-
sibility of ocular or systemic disease are absent. This enhances the reliability of our findings, which confirm the 
link between glaucoma surgery and mortality, thereby serving as important evidence regarding the relationship 
between glaucoma and mortality.
We investigated the cause-specific hazard of mortality by analyzing OAG and ACG separately. Interestingly, 
these two types of glaucoma were associated with increased hazard for mortality of different causes. Patients 
with OAG showed an increased risk of death due to all, vascular, pulmonary, neurologic, and infectious causes; 
however, these were not significant. On the other hand, patients with ACG showed an increased risk of mortality 
due to all causes. In particular, glaucoma surgery was significantly associated with an increase in the risk for all-
cause mortality, mortality caused by cancer, and accident or trauma-related mortality in patients with ACG, who 
are known to have an approximately three-fold increased risk of having severe binocular vision loss compared to 
patients with  OAG28,29. In a recent meta-analysis, the pooled relative risk of mortality due to visual impairment 
was 1.3630. In another national sample cohort study, the blindness group showed a 1.54 times increased risk of 
mortality compared with the control  group4. Additionally, another study, in which the Beijing Eye Study was 
evaluated, suggested the presence of a strong association between mortality and primary ACG but not between 
mortality and primary  OAG12. Therefore, it could be considered that the results of the present study, demonstrat-
ing a remarkable increase in the risk of mortality related with glaucoma surgery for ACG, are reliable.
Adjusted HR for cancer-related mortality associated with glaucoma surgery for ACG was 2.03 (P = 0.029). A 
recent study using national insurance data to identify the risk of cancer in patients with glaucoma showed that 
the adjusted HR for cancer was 1.049 with varying HRs for different types of  cancer31. Chronic inflammation and 
environmental factors such as smoking are thought to influence the relationship between cancer and glaucoma. 
However, the risks of cancer development in patients with OAG or ACG were not assessed in previous studies. 
We found conflicting results in the analysis of the effects of glaucoma surgery on the risk of cancer-related death 
in patients with OAG and ACG. Thus, if researchers wish to conduct further studies on the association between 
glaucoma, cancer, and mortality, classifying the types of glaucoma is necessary.
In the present study, risk of mortality due to accident or trauma was significantly increased fourfold by glau-
coma surgery for ACG. However, with OAG, the HR of mortality caused by accident or trauma was 0.63 and was 
Table 2.  Mortality rates of Korean elderly patients according to history of glaucoma surgery. Cox model with 
glaucoma surgery status as a time-varying covariate. CI confidence interval.
Cause of mortality
Mortality rate, No. of deaths/total person-years
(incidence per 1000 Person-years; 95% CI)
Surgery group Non-surgery group
All-cause 83/2388 (34.76; 28.03–43.10) 2951/105,850 (27.88; 26.89–28.90)
Cancer 21/2388 (8.79; 5.73–13.49) 860/105,850 (8.12; 7.60–8.69)
Vascular 17/2388 (7.12; 4.43–11.45) 695/105,850 (6.57; 6.10–7.07)
Pulmonary 9/2388 (3.77; 1.96–7.24) 322/105,850 (3.04; 2.73–3.39)
Neurologic 6/2388 (2.51; 1.13–5.59) 98/105,850 (0.93; 0.76–1.13)
Infectious 2/2388 (0.84; 0.21–3.35) 86/105,850 (0.81; 0.66–1.00)
Accident or trauma 7/2388 (2.93; 1.40–6.15) 227/105,850 (2.14; 1.88–2.44)
Table 3.  Hazard ratios of total and cause-specific mortality in Korean elderly patients according to history 
of glaucoma surgery. CI confidence interval, DM diabetes mellitus. a Cox model with vitreoretinal surgery 
status as a time-varying covariate. b Adjusted for age and sex. c Adjusted for age, sex, income, region, 
Charlson Comorbidity Index score (0, 1, 2, 3, 4, ≥ 5), age-related macular degeneration, DM with ophthalmic 
manifestations, and cataract severity. d Adjusted for age, sex, income, region, Charlson Comorbidity Index score 
(0, 1, 2, 3, 4, ≥ 5), age-related macular degeneration, DM with ophthalmic manifestations, cataract severity, 
smoking, drinking, exercise, and body mass index.
Cause of mortality (No. 
of participants)
Unadjusted cox model
Hazard ratio (95% CI)a P-value
Adjusted cox model
Hazard Ratio (95% CI)a,b P-value
Adjusted cox model
Hazard ratio (95% CI)a,c P-value
Adjusted cox model
Hazard ratio (95% CI)a,d P-value
All-cause 1.16 (0.93–1.43) 0.184 1.28 (1.03–1.59) 0.023 1.29 (1.04–1.60) 0.020 1.31 (1.05–1.62) 0.014
Cancer 1.06 (0.69–1.63) 0.792 1.14 (0.74–1.76) 0.541 1.16 (0.75–1.79) 0.505 1.17 (0.75–1.80) 0.487
Vascular 0.98 (0.61–1.58) 0.938 1.10 (0.68–1.78) 0.698 1.11 (0.68–1.79) 0.683 1.12 (0.69–1.80) 0.654
Pulmonary 1.09 (0.56–2.10) 0.805 1.25 (0.64–2.41) 0.514 1.22 (0.63–2.34) 0.555 1.26 (0.66–2.40) 0.488
Neurologic 2.30 (1.02–5.22) 0.045 2.59 (1.15–5.84) 0.022 2.71 (1.20–6.12) 0.017 2.66 (1.18–6.00) 0.018
Infectious 0.93 (0.23–3.80) 0.917 1.02 (0.25–4.17) 0.975 1.02 (0.25–4.22) 0.979 1.03 (0.25–4.26) 0.971
Accident or trauma 1.38 (0.65–2.91) 0.403 1.49 (0.71–3.14) 0.297 1.59 (0.75–3.36) 0.225 1.61 (0.77–3.39) 0.209
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not significant. Restrictions in daily activities such as walking, balancing, and driving not only reduce the quality 
of life but also increase mortality in patients with  glaucoma32. Several studies have shown that visual impairment 
related with glaucomatous damage is associated with motor vehicle collisions and falls, which are major causes of 
death related to unintended  injury33–39. Since our study was conducted using claims data, there were limitations in 
accurately evaluating the visual functions of the patients. Additionally, since severity of impaired visual function, 
whether binocular or monocular, and location of visual field defects are important factors in evaluating the effect 
Table 4.  Hazard ratios of mortality in Korean elderly patients with glaucoma according to age, sex, residence, 
income, Charlson comorbidity index score, and ocular comorbidities. Glaucoma diagnosis group was used as 
a reference in all models. Adjusted for age, sex, income, region, Charlson Comorbidity Index score (0, 1, 2, 3, 
4, and ≥ 5), age-related macular degeneration, DM with ophthalmic manifestations, cataract severity, smoking, 
drinking, exercise, and BMI. BMI body mass index, CCI Charlson Comorbidity Index, DM diabetes mellitus.
Adjusted hazard ratio (95% CI) P-value P-value for interaction
Age (years) 0.198
 < 70 1.79 (1.27–2.53) 0.001
70–74 1.17 (0.77–1.78) 0.455
75–79 0.91 (0.58–1.45) 0.700
80–84 1.22 (0.61–2.45) 0.580
 ≥ 85 1.10 (0.47–2.55) 0.833
Sex 0.096
Male 1.53 (1.17–2.00) 0.002
Female 1.05 (0.73–1.50) 0.797
Residence 0.233
Metropolitan 1.55 (1.09–2.21) 0.015
Provincial 1.18 (0.90–1.55) 0.219
Income 0.260
Below 20 percentiles 1.63 (1.06–2.50) 0.025
Above 20 percentiles 1.23 (0.96–1.57) 0.102
CCI 0.214
0 1.49 (0.84–2.62) 0.172
1 1.30 (0.73–2.33) 0.377
2 1.71 (1.02–2.89) 0.043
3 0.43 (0.16–1.12) 0.084
4 1.16 (0.61–2.18) 0.654
 ≥ 5 1.53 (1.08–2.16) 0.016
Age-related macular degeneration 0.669
No 1.32 (1.06–1.64) 0.013
Yes 1.01 (0.30–3.40) 0.993
DM with ophthalmic manifestations 0.299
No 1.25 (0.99–1.58) 0.059
Yes 1.76 (0.96–3.20) 0.066
Severe cataract
No 1.33 (1.05–1.70) 0.019 0.713
Yes 1.21 (0.77–1.91) 0.415
Smoking status 0.585
Non-smoker 1.35 (1.06–1.71) 0.016
Ex-smoker 0.84 (0.34–2.06) 0.697
Current smoker 1.41 (0.82–2.41) 0.210
Alcohol consumption 0.834
No 1.32 (1.03–1.69) 0.027
Yes 1.26 (0.82–1.92) 0.293
Regular exercise 0.090
No 1.21 (0.96–1.53) 0.114
Yes 1.98 (1.18–3.32) 0.010
BMI 0.542
 < 23 1.49 (1.10–2.02) 0.010
23–24.9 1.27 (0.80–1.99) 0.308
 ≥ 25 1.12 (0.75–1.69) 0.571
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of visual functional damage on the quality of life of patients with glaucoma regardless of angle status, further 
studies are required to determine the reasons for the obvious differences between the hazards of cause-specific 
mortality associated with glaucoma surgery for the two types of glaucoma. However, considering the character-
istics of ACG, which has a higher possibility of causing serious decline in visual function than does OAG, the 
possibility of progressed glaucomatous impairment of visual function, which is implied by a history of glaucoma 
surgery, and the fact that the risk of trauma-related death increases with age, our finding regarding trauma and 
accident-related mortality can be considered reliable and useful for the follow-up of patients aged over 60 years 
who underwent surgery for ACG. Furthermore, the significance of the findings of our study reflects the fact that 
deaths associated with trauma and accident can be sufficiently prevented by the efforts of patients and doctors.
This study has several limitations. First, it was a retrospective study. Second, since we used national medical 
claims data, clinical information on disease diagnosis or severity was insufficient. Other factors that could poten-
tially affect the transition from medical treatment to surgical treatment could not be included in our analyses. In 
addition, only patients who visited medical facilities were included in this study. Third, this study was conducted 
on patients aged ≥ 60 years with OAG and ACG; this should be considered when applying our results regarding 
the association of glaucoma surgery and increased risk of mortality to clinical practice. Finally, although we 
used a large database, the population consisted of mostly Koreans. Considering that Asians account for about 
77% of the world’s primary ACG cases, the racial restrictions of the study population may affect the results of 
our subgroup analysis according to the type of glaucoma.
In summary, we demonstrated that glaucoma surgery was significantly associated with an increase in mortal-
ity in elderly Korean patients with OAG and ACG. The adjusted HR for mortality related with glaucoma surgery 
increased by about 30%. The results of our study showed that the risk of mortality due to neurologic causes was 
significantly increased, 2.66-fold. The increase in the risk of mortality due to neurologic causes was marginal in 
patients with OAG, whereas cancer and accident or trauma-related mortality risks were significantly increased 
in patients with ACG. These suggest that continuous surveillance by healthcare providers and patients during 
follow-up is necessary for the reduction and prevention of deaths of patients who undergo glaucoma surgery. 
Additionally, we believe that it is important to detect and treat glaucoma early to minimize the need for surgical 
treatment.
Methods
Study design. This was a population-based retrospective cohort study conducted using the KNHIS-Senior 
database. The health insurance system in South Korea is a nationwide universal single payer system managed 
by the KNHIS. The KNHIS-Senior database is one of the databases provided by the KNHIS. It includes the data 
of 558,147 individuals randomly sampled from 10% of the approximately 5.5 million South Korean population 
aged > 60 years and includes information on age, sex, general health examinations, hospital and pharmacy visits, 
disease diagnoses, status, procedures, and prescribed medications. The general health examination database 
includes the results of the health screening examination conducted by the  KNHIS40.
Table 5.  Hazard ratios of total and cause-specific mortality in Korean elderly patients with open-angle 
glaucoma and angle closure glaucoma according to history of glaucoma surgery. DM diabetes mellitus. a Cox 
model with vitreoretinal surgery status as a time-varying covariate. b Adjusted for age and sex. c Adjusted for 
age, sex, income, region, Charlson Comorbidity Index (0, 1, 2, 3, 4, and ≥ 5), age-related macular degeneration, 
DM with ophthalmic manifestations, and cataract severity. d Adjusted for age, sex, income, region, 
Charlson Comorbidity Index (0, 1, 2, 3, 4, and ≥ 5), age-related macular degeneration, DM with ophthalmic 
manifestations, cataract severity, smoking, drinking, exercise, and body mass index.
Cause of mortality (No. 
of participants)
Unadjusted cox model
Hazard ratio (95% CI)a P-value
Adjusted cox model
Hazard ratio (95% CI)a,b P-value
Adjusted cox model
Hazard ratio (95% CI)a,c P-value
Adjusted cox model
Hazard ratio (95% CI)a,d P-value
Open-angle glaucoma
All-cause 1.03 (0.79–1.35) 0.816 1.10 (0.84–1.44) 0.482 1.10 (0.84–1.43) 0.498 1.12 (0.86–1.46) 0.413
Cancer 0.79 (0.43–1.43) 0.434 0.81 (0.45–1.48) 0.496 0.81 (0.45–1.48) 0.499 0.82 (0.45–1.50) 0.522
Vascular 0.96 (0.54–1.71) 0.894 1.05 (0.59–1.86) 0.878 1.04 (0.59–1.85) 0.884 1.07 (0.60–1.89) 0.828
Pulmonary 1.15 (0.55–2.41) 0.714 1.24 (0.59–2.62) 0.570 1.21 (0.58–2.52) 0.603 1.27 (0.62–2.62) 0.519
Neurologic 2.14 (0.80–5.75) 0.132 2.37 (0.89–6.33) 0.085 2.47 (0.93–6.57) 0.071 2.41 (0.91–6.39) 0.078
Infectious 1.35 (0.33–5.57) 0.677 1.45 (0.35–5.93) 0.608 1.44 (0.34–5.99) 0.619 1.46 (0.35–6.12) 0.604
Accident or trauma 0.56 (0.14–2.27) 0.418 0.58 (0.15–2.31) 0.442 0.62 (0.16–2.46) 0.496 0.63 (0.16–2.51) 0.516
Angle closure glaucoma
All-cause 1.57 (1.09–2.25) 0.015 1.80 (1.26–2.58) 0.001 1.83 (1.26–2.64) 0.001 1.82 (1.27–2.62) 0.001
Cancer 1.76 (0.93–3.34) 0.081 1.99 (1.07–3.71) 0.030 2.03 (1.08–3.84) 0.028 2.03 (1.07–3.83) 0.029
Vascular 1.11 (0.46–2.67) 0.822 1.27 (0.52–3.09) 0.595 1.27 (0.53–3.06) 0.593 1.25 (0.52–2.98) 0.616
Pulmonary 1.05 (0.25–4.35) 0.949 1.32 (0.32–5.44) 0.702 1.24 (0.29–5.28) 0.768 1.25 (0.30–5.27) 0.762
Neurologic 2.78 (0.63–12.27) 0.176 3.10 (0.70–13.76) 0.137 3.22 (0.71–14.58) 0.129 3.22 (0.71–14.62) 0.130
Infectious – – – – – – – –
Accident or trauma 3.36 (1.31–8.61) 0.011 3.78 (1.47–9.71) 0.006 4.04 (1.57–10.41) 0.004 4.00 (1.55–10.34) 0.004
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The baseline information of the individuals was collected during health screening examinations. Data on 
smoking habits, alcohol habits, and regular exercise were collected using self-administered questionnaires. 
Height, weight, and blood pressure were measured, and BMI was calculated as weight in kilograms divided by 
height in meters squared.
The KNHIS uses the Korean Electronic Data Interchange (KEDI) codes and the Korean Standard Classifica-
tion of Diseases (KCD) codes, a system similar to the International Classification of Diseases (ICD). This study 
was conducted according to the ethical principles outlined in the Declaration of Helsinki. Informed consent was 
not obtained because anonymized and de-identified information was used for analyses. As KNHIS-Senior data-
base comprises publicly opened data, the Institutional Review Board of Asan Medical Center and the University 
of Ulsan College of Medicine approved a waiver for reviewing this study (2020-1197).
Study population. We selected the study population from those included in the KNHIS-Senior database 
between January 1, 2002, and December 31, 2015. To minimize the impact of surveillance bias, we set a wash-
out period between January 1, 2002, and December 31, 2002. The inclusion criterion was the presence of at least 
one NHIS record with the following conditions: a KCD-7 code for OAG (H401) or ACG (H402) between Janu-
ary 1, 2003, and December 31, 2012, and glaucoma surgery between January 1, 2003, and December 30, 2015 
(Table 6). The eligible individuals were classified into a glaucoma surgery group, which consisted of patients with 
ICD-10 diagnosis codes for OAG or ACG and KEDI codes for glaucoma surgeries, and a glaucoma diagnosis 
group, which included people with glaucoma diagnosis codes, but without a KEDI code for glaucoma surgeries. 
Patients with age less than 60 years and codes for secondary glaucoma were excluded.
Exposure and outcome. The exposure of interest was glaucoma surgery. Both the glaucoma surgery and 
glaucoma diagnosis groups were followed up from the date of the initial diagnosis of glaucoma. The primary 
outcome of interest was total and cause-specific mortality at any point from the time of patient inclusion in the 
study until the end of the study on December 31, 2015. Mortality status was confirmed using an indicator vari-
able in the KNHIS-Senior database, which contains information on total and cause-specific mortality. Causes of 
death were grouped into cancer, vascular, pulmonary, neurologic, infectious, accident or trauma-related condi-
tions (Supplementary Table S3).
For the glaucoma surgery group, the time between glaucoma diagnosis and surgery was defined as the follow-
up period for glaucoma diagnosis, and the time after surgery was defined as the follow-up period for glaucoma 
 surgery41. For the glaucoma diagnosis group, time until death was calculated as the number of days from glau-
coma diagnosis to  death41. Individuals with no death record in the database were censored on the last known 
date or on December 31, 2015, if still enrolled.
Covariates. Information on sociodemographic factors, including age at the time of glaucoma diagnosis, sex, 
residence (metropolitan areas, including Seoul and large cities, and provincial regions, including small cities and 
rural areas), household income level (categorized below or above 20% of median income), smoking and alcohol 
habits, regular exercise, and BMI, were obtained from the database. The CCI  score42,43 was used as a covariate 
to represent overall general health status for matching between two groups. It is a weighted index of systemic 
disease burden according to the presence or absence of 17 systemic diseases. The higher the CCI score, the 
higher the systemic disease burden. Individuals with a CCI score of 0 to 6 points, which can be used to predict 
the risk of one-year mortality, were classified according to their systemic disease profiles. Ocular comorbidities 
such as age-related macular degeneration, DM with ophthalmic manifestations, and severe cataract were also 
used as matching variables. KCD-7 codes for systemic and ocular comorbidities are presented in Supplementary 
Table S4.




S5038 Stent insertion in sub-conjunctiva
S5039 Stent insertion in Schlemm’s cannal
S5040 Nonpenetrating filtration surgery (Deep sclerectomy, Viscocanalostomy)
S5042 Filtration operation (sclerotomy, sclerectomy,
S5043 Trabeculectomy with laser
S5044 Photocoagulation for iris, Ciliary body
S5045 Cyclocryotherapy
S5047 Trabeculotomy under microscopy
S5048 Schlemm’s canal opening under microscopy
S5049 Glaucoma implant surgery
SZ670 Glaucoma aqueous tube insertion
8
Vol:.(1234567890)
Scientific Reports |        (2021) 11:17055  | https://doi.org/10.1038/s41598-021-96063-7
www.nature.com/scientificreports/
Statistical analysis. Patient characteristics and mortality rates were descriptively compared according 
to glaucoma surgery status. Cox regression models with glaucoma surgery status (exposure) as time-varying 
covariates were used to obtain covariate-adjusted associations between glaucoma surgery and time until death 
due to any cause and between glaucoma surgery and time until death attributed to cancer, vascular, pulmonary, 
neurologic, infectious, accident or trauma-related conditions. HR and 95% CIs were calculated. Three models 
with increasing degrees of adjustment to account for potential confounding factors at baseline were used. Model 
1 was adjusted for age (< 70, 70–74, 75–79, 80–84, and ≥ 85 years) and sex. Model 2 was additionally adjusted for 
income level, region, CCI, age-related macular degeneration, DM with ophthalmic manifestations, and severe 
cataract. In model 3, smoking status (non-smoker, ex-smoker, current smoker), alcohol intake (no, yes), exercise 
(no, yes), and BMI (continuous) were additionally adjusted.
All statistical analyses were conducted using the Statistical Analysis System (SAS) software version 9.4 (SAS 
Institute, Cary, NC, United States), and a two-sided P value of < 0.05 was considered statistically significant. To 
compare the baseline characteristics between the groups, ASD, calculated as the difference between means or 
proportions divided by a pooled estimate of the standard deviation, was used. Unlike the traditional methods 
used to test for significance, ASD is insensitive to sample size. Therefore, it is useful for identifying meaningful 
differences. An ASD value of > 0.1 was considered clinically  significant44.
Data availability
The data that support the findings of this study are available from NHIS, but restrictions apply to the availability 
of these data, which were used under license for the current study; therefore, these are not publicly available. 
Data are, however, available from the authors upon reasonable request and with permission of NHIS.
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